King's College London
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Schizophrenia
FollowWhat is new in Schizophrenia research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- 10-20 mg Aripiprazole oral solution filmPhase 3 · NCT06799559
- 3-6mg QLM1016Phase 3 · NCT06799559
- aripiprazolePhase 3 · NCT07565428 · NCT07911787
- Aripiprazole tabletsPhase 3 · NCT06589817
- AtorvastatinPhase 3 · NCT07045142
- BrilaroxazinePhase 3 · NCT05184335
- BupropionPhase 3 · NCT05603104
- Cannabidiol (CBD)Phase 3 · NCT07434973
- Cannabidiol oral solutionPhase 3 · NCT04411225
- CariprazinePhase 3 · NCT03817502 · NCT07715253
- CBD 100 mg/mL Oral SolutionPhase 3 · NCT07326124 · NCT06778564
- ClozapinePhase 3 · NCT05603104
- D-serine solutionPhase 3 · NCT07263022
- EmpagliflozinPhase 3 · NCT05669742
- EscitalopramPhase 3 · NCT05603104
- Esketamine hydrochloridePhase 3 · NCT05603104
- Esketamine Nasal ProductPhase 3 · NCT05603104
- Evenamide 15 mg bidPhase 3 · NCT07184619
- HS-10380Phase 3 · NCT07759869 · NCT07911787
- Hydrochloride Carliprazine capsulesPhase 3 · NCT06589817
- iloperidonePhase 3 · NCT06961968
- KarX-ECPhase 3 · NCT06947941 · NCT07424404
- KarXTPhase 3 · NCT06947941 · NCT07424404 · NCT06882785 · NCT06585787 · NCT07288567 · NCT07061288
- KarXT + KarX-EC Arm Matching PlaceboPhase 3 · NCT06947941
- Ketamine HydrochloridePhase 3 · NCT05603104 · NCT04589208
- LB-102Phase 3 · NCT07369154
- LB-102 (100 mg tablet)Phase 3 · NCT07363577
- LB-102 (50 mg tablet)Phase 3 · NCT07363577
- LithiumPhase 3 · NCT05603104
- LumateperonePhase 3 · NCT06229210
- Lumateperone 42 mgPhase 3 · NCT06482554
- MetforminPhase 3 · NCT07045142
- ModafinilPhase 3 · NCT07231497 · NCT07263022
- NBI-1117568Phase 3 · NCT07114874 · NCT07227818 · NCT06963034 · NCT07105098
- OlanzapinePhase 3 · NCT05303064 · NCT05669742 · NCT07565428 · NCT03781115
- OLZ/SAMPhase 3 · NCT05303064 · NCT04987229
- OPC-34712FUM/ Brexpiprazole fumaratePhase 3 · NCT05325645
- Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NACPhase 3 · NCT05796401
- PlacebPhase 3 · NCT07326124
- QuetiapinePhase 3 · NCT05603104
- RisperidonePhase 3 · NCT04105231 · NCT07565428
- Risperidone 2 mgPhase 3 · NCT06482554
- RoluperidonePhase 3 · NCT07565428
- Second-line AntidepressantsPhase 3 · NCT05603104
- Second-line AntipsychoticsPhase 3 · NCT05603104
- Semaglutide + TAUPhase 3 · NCT07770282
- SEP-363856Phase 3 · NCT07225712 · NCT06894212
- SertralinePhase 3 · NCT05603104
- TiagabinePhase 3 · NCT00179465
- Valproate acidPhase 3 · NCT05603104
- VenlafaxinePhase 3 · NCT05603104
- Xanomeline/Trospium ChloridePhase 3 · NCT07686263
- 150 mg B2227Phase 2/3 · NCT07722728
- 30 mg B2227Phase 2/3 · NCT07722728
- 70 mg B2227Phase 2/3 · NCT07722728
- Brexpiprazole for ER injection, 100 mgPhase 2/3 · NCT07742280
- Brexpiprazole for ER injection, 45 mgPhase 2/3 · NCT07742280
- MitoQPhase 2/3 · NCT06191965
- NaBen®Phase 2/3 · NCT03094429
- Vraylar® 1.5 mgPhase 2/3 · NCT07722728
- Vraylar® 3.0 mgPhase 2/3 · NCT07722728
- Vraylar® 4.5 mgPhase 2/3 · NCT07722728
- Vraylar® 6.0 mgPhase 2/3 · NCT07722728
- ALTO-101Phase 2 · NCT06502964
- ALTO-101 Transdermal Delivery SystemPhase 2 · NCT06502964
- ANAVEX3-71 oral capsulesPhase 2 · NCT06245213
- Aripiprazole tabletPhase 2 · NCT07703956
- BR5402APhase 2 · NCT06821945
- BR5402A-1Phase 2 · NCT06821945
- BR5402BPhase 2 · NCT06821945
- BR5402B-1Phase 2 · NCT06821945
- BR5402CPhase 2 · NCT06821945
- BR5402C-1Phase 2 · NCT06821945
- BR5402DPhase 2 · NCT06821945
- BR5402D-1Phase 2 · NCT06821945
- BrenipatidePhase 2 · NCT07410507
- Buprenorphine 0.15 MG [Belbuca]Phase 2 · NCT05778591
- CannabidiolPhase 2 · NCT04105231
- Cannabidiol as add-onPhase 2 · NCT02926859
- clemastine (8 mg/day)Phase 2 · NCT06315972
- DasatinibPhase 2 · NCT05838560
- Deferiprone (DFP)Phase 2 · NCT07759895
- DSP-2342Phase 2 · NCT07850102
- EmraclidinePhase 2 · NCT07145918
- GXV813Phase 2 · NCT07467993
- Inert CompoundPhase 2 · NCT04226898
- Intravenous immunoglobulinPhase 2 · NCT03194815
- ITI-1284Phase 2 · NCT06540833
- LY03020Phase 2 · NCT07396870 · NCT07292233 · NCT07230652
- ML-007C-MAPhase 2 · NCT06887192 · NCT07459660 · NCT07459647
- N-Acetyl Cysteine (NAC)Phase 2 · NCT07759895
- NBI-1117570Phase 2 · NCT07288333
- NMDAEPhase 2 · NCT05052853 · NCT06021197 · NCT07122895 · NCT04745143
- NMDAE plus AIFAPhase 2 · NCT05240976 · NCT04917302
- NMDAE plus AOPhase 2 · NCT04959201
- NMDAE plus Placebo CapPhase 2 · NCT05240976 · NCT04959201 · NCT04917302
- NS-136Phase 2 · NCT07521683
- Oxytocin nasal sprayPhase 2 · NCT06881810
- quercetinPhase 2 · NCT05838560
- RituximabPhase 2 · NCT04323566 · NCT05622201 · NCT03194815
- S1RA plus NMDAEPhase 2 · NCT06574360
- S1RA plus Placebo CapPhase 2 · NCT06574360
- Sodium Benzoate 2gram/dayPhase 2 · NCT06340789
- SPG302Phase 2 · NCT06442462
- Synbiotic SupplementPhase 2 · NCT04226898
- TirzepatidePhase 2 · NCT06939088
- Transcranial magnetic stimulationPhase 2 · NCT06376734
- UblituximabPhase 2 · NCT07680946
- Use of antipsychotic treatment with marketing authorization at doses lower than those recommended: - Olanzapine - Zuclopenthixol - Risperidone - Pipotiazine palmitate / Pipotiazine - Quetiapine - FlupPhase 2 · NCT07152184
- VV119 2mgPhase 2 · NCT07703956
- VV119 4mgPhase 2 · NCT07703956
- VV119 6mgPhase 2 · NCT07703956
- AcetazolamidePhase 1/2 · NCT04887792
- Cariprazine DepotPhase 1/2 · NCT07185815
- Cariprazine Depot MTDPhase 1/2 · NCT07185815
- CromoglycatePhase 1/2 · NCT03794076
- MDMA 120mgPhase 1/2 · NCT05770375
- MDMA 40mgPhase 1/2 · NCT05770375
- MDMA 80mgPhase 1/2 · NCT05770375
- Ocrelizumab infusionPhase 1/2 · NCT03971487
- Oral Cariprazine 3 mg/dayPhase 1/2 · NCT07185815
- SIPI6398 TabletsPhase 1/2 · NCT07626034
- Xanomeline and trospium chloride (KarXT)Phase 1/2 · NCT07423546
- Xingqi Daozhi DecoctionPhase 1/2 · NCT07767526
- [11C] PHNOPhase 1 · NCT07715253
- [11C]UCB-J radiotracerPhase 1 · NCT04038840
- 14C-SEP-380135Phase 1 · NCT07455084
- AticaprantPhase 1 · NCT07615426
- AX251 LAI 135 mgPhase 1 · NCT07484204
- AX251 LAI 180 mgPhase 1 · NCT07484204
- AX251 LAI 45 mgPhase 1 · NCT07484204
- AX251 LAI 90 mgPhase 1 · NCT07484204
- BrexpiprazolePhase 1 · NCT07715253
- Brexpiprazole long-acting injectionPhase 1 · NCT06674694
- BXCL501 120 MicrogramsPhase 1 · NCT05025605
- BXCL501 60 MicrogramsPhase 1 · NCT05025605
- BXCL501 80 MicrogramsPhase 1 · NCT05025605
- Delta-9-THC Medium DosePhase 1 · NCT06058702
- Delta-9-THC Very Low DosePhase 1 · NCT06058702
- HHK101-Multiple Dose 1Phase 1 · NCT07815210
- HHK101-Multiple Dose 2Phase 1 · NCT07815210
- HHK101-Multiple Dose 3Phase 1 · NCT07815210
- HHK101-Single Dose 1Phase 1 · NCT07815210
- HHK101-Single Dose 2Phase 1 · NCT07815210
- HHK101-Single Dose 3Phase 1 · NCT07815210
- HHK101-Single Dose 4Phase 1 · NCT07815210
- HHK101-Single Dose 5Phase 1 · NCT07815210
- KR23248Phase 1 · NCT07585383
- LTX-001 once dailyPhase 1 · NCT07734493
- LTX-001 twice dailyPhase 1 · NCT07734493
- LY03017Phase 1 · NCT06980207 · NCT06793995
- LY03017-PlaceboPhase 1 · NCT06980207
- Matching PlaceboPhase 1 · NCT07585383
- MemantinePhase 1 · NCT04789915
- PET-MRPhase 1 · NCT04038840
- VV119 （in healthy adult subjects）Phase 1 · NCT06504290
- VV119 Placebo （in adult patients with schizophrenia）Phase 1 · NCT06504290
- VV119 Placebo （in healthy adult subjects）Phase 1 · NCT06504290
- VV119 Placebo(SAD)Phase 1 · NCT06105151
- VV119(FE)Phase 1 · NCT06105151
- VV119(in adult patients with schizophrenia)Phase 1 · NCT06504290
- VV119(SAD)Phase 1 · NCT06105151
- XEP527Phase 1 · NCT07908680
- ZiprasidonePhase 1 · NCT03781115
- Antipsychotics plus Levothyroxine SodiumEarly phase 1 · NCT07011953
- Antipsychotics plus PlaceboEarly phase 1 · NCT07011953
- hDFSCs-ExoEarly phase 1 · NCT07485751
- Low Dose THCEarly phase 1 · NCT02102113
- NTX-253Early phase 1 · NCT07344948
- Rivastigmine Transdermal SystemEarly phase 1 · NCT04366518
- ScopolamineEarly phase 1 · NCT04366518
- Very Low Dose THCEarly phase 1 · NCT02102113
Closest to patients
- Safety and Efficacy of Brilaroxazine (RP5063) in SchizophreniaSafety and Efficacy of Brilaroxazine (RP5063) in SchizophreniaReviva Pharmaceuticals (sponsor) · 17 hospitals in United StatesPhase 3Primary completion 2025
- Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia PatientsEmpagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia PatientsTanta Unuversity · Tanta, EgyptPhase 3Results expected 2026
- A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute SchizophreniaA Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute SchizophreniaChengdu Kanghong Pharmaceutical Group Co., Ltd. (sponsor)Phase 3Results expected 2026
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Case report
Persistent Amotivation After Cannabis-Related Psychosis: Diagnostic Challenges and Clinical Course With Electroconvulsive Therapy: A Case Report.
Persistent Amotivation After Cannabis-Related Psychosis: Diagnostic Challenges and Clinical Course With Electroconvulsive Therapy: A Case Report.
Neuropsychopharmacology reports
PubMed · PMID 42963078Systematic review
Examining the links between vitamin C and schizophrenia spectrum disorders: a systematic review and meta-analysis on circulating levels and supplementation outcomes.
Examining the links between vitamin C and schizophrenia spectrum disorders: a systematic review and meta-analysis on circulating levels and supplementation outcomes.
Frontiers in nutrition
PubMed · PMID 42952622Publication
Response Surface Methodology-Guided Development of Hot-Melt-Extruded Cannabidiol Solid Self-Emulsifying Drug Delivery Systems for Enhanced Drug Release and Stability.
Response Surface Methodology-Guided Development of Hot-Melt-Extruded Cannabidiol Solid Self-Emulsifying Drug Delivery Systems for Enhanced Drug Release and Stability.
Pharmaceutics
PubMed · PMID 42942832Publication
Hepato-Immune Crosstalk Underlies Antipsychotic-Associated Metabolic Dysregulation in Schizophrenia: Quercetin as a Therapeutic Candidate for High-Inflammatory Subtypes.
Hepato-Immune Crosstalk Underlies Antipsychotic-Associated Metabolic Dysregulation in Schizophrenia: Quercetin as a Therapeutic Candidate for High-Inflammatory Subtypes.
Metabolites
PubMed · PMID 42941208
Find fellow researchers
Groups with active Schizophrenia work.
Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Centro de Investigación Biomédica en Red de Salud Mental
Madrid, Spain
Team details appear once the team leader joins.
Is this your team? Claim it
Yale University
New Haven, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Charité – Universitätsmedizin Berlin
Berlin, Germany
Team details appear once the team leader joins.
Is this your team? Claim it
Deutsches Zentrum für Psychische Gesundheit
Berlin, Germany
Team details appear once the team leader joins.
Is this your team? Claim it
University of Toronto
Toronto, Canada
Team details appear once the team leader joins.
Is this your team? Claim it
Instituto de Salud Carlos III
Madrid, Spain
Team details appear once the team leader joins.
Is this your team? Claim it
University of Oxford
Oxford, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Shanghai Jiao Tong University
Shanghai, China
Team details appear once the team leader joins.
Is this your team? Claim it
University of Copenhagen
Copenhagen, Denmark
Team details appear once the team leader joins.
Is this your team? Claim it
The University of Melbourne
Melbourne, Australia
Team details appear once the team leader joins.
Is this your team? Claim it